JPMorgan Chase & Co. Boosts Holdings in Simulations Plus, Inc. $SLP

JPMorgan Chase & Co. boosted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLPFree Report) by 154.7% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 167,646 shares of the technology company’s stock after purchasing an additional 101,822 shares during the period. JPMorgan Chase & Co. owned approximately 0.83% of Simulations Plus worth $2,526,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of SLP. Raymond James Financial Inc. purchased a new stake in shares of Simulations Plus in the second quarter worth about $25,000. Quarry LP purchased a new position in Simulations Plus during the third quarter valued at approximately $28,000. CWM LLC raised its position in Simulations Plus by 3,729.1% during the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock valued at $32,000 after acquiring an additional 2,051 shares in the last quarter. Farther Finance Advisors LLC acquired a new position in Simulations Plus in the third quarter valued at approximately $40,000. Finally, US Bancorp DE lifted its holdings in Simulations Plus by 32.5% in the third quarter. US Bancorp DE now owns 6,167 shares of the technology company’s stock valued at $93,000 after acquiring an additional 1,513 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Price Performance

Shares of SLP stock opened at $11.99 on Monday. Simulations Plus, Inc. has a 1-year low of $11.09 and a 1-year high of $36.45. The company has a market cap of $241.60 million, a price-to-earnings ratio of -3.75 and a beta of 1.19. The stock has a 50 day simple moving average of $13.06 and a 200-day simple moving average of $16.06.

Simulations Plus (NASDAQ:SLPGet Free Report) last released its quarterly earnings results on Thursday, January 8th. The technology company reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.05). The company had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period in the prior year, the business posted $0.17 EPS. Analysts anticipate that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. BTIG Research cut shares of Simulations Plus from a “buy” rating to a “neutral” rating in a research note on Thursday, December 18th. Wall Street Zen cut shares of Simulations Plus from a “buy” rating to a “hold” rating in a research note on Saturday. Zacks Research downgraded shares of Simulations Plus from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. Citigroup restated a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Finally, TD Cowen reaffirmed a “hold” rating on shares of Simulations Plus in a report on Thursday, January 8th. Three equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $25.00.

Get Our Latest Analysis on SLP

Simulations Plus Company Profile

(Free Report)

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.

See Also

Institutional Ownership by Quarter for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.